Grifols Among Federal Partners Working to Develop Virus Therapy

The Department of Health and Human Services is partnering with the American Red Cross and three biotechnology companies to develop immunotherapies for patients with Covid-19, it announced Monday.

The HHS’s Biomedical Advanced Research and Development Authority will work with Emergent BioSolutions, Grifols USA, and SAb Biotherapeutics. The aim is to see if they can use the antibodies from people who have survived Covid-19 to stimulate the immune systems of those who are currently ill, the HHS said.

“Together, we are hyper focused on a single goal, to save lives,” said BARDA Director Rick Bright. BARDA helps develop countermeasures against emerging ...